Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.72 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1186921 | 0.77 | NOTUM (0.62) | NOTUMLMNAHSD17B10HPGDHTT | |
| SCHEMBL30310181 | 0.77 | NOTUM (0.62) | NOTUMLMNAHSD17B10HPGDHTT | |
| SCHEMBL16114401 | 0.77 | LMNA (0.75) | CYP19A1LTA4HLMNAHPGDHTT | |
| SCHEMBL28012602 | 0.77 | TLR8 (0.68) | TLR8NOTUMLMNATSHRHPGD | |
| SCHEMBL6386042 | 0.76 | TLR8 (0.73) | TLR8NOTUMLMNATSHRHPGD | |
| SCHEMBL6388915 | 0.76 | TLR8 (0.73) | TLR8L3MBTL1NOTUMTSHRHSD17B10 | |
| Hydrochloric Acid SCHEMBL27783346 | 0.76 | NOTUM (0.60) | NOTUMLMNAHSD17B10HPGDHTT | |
| SCHEMBL3531828 | 0.75 | KDM4E (0.52) | CYP19A1LTA4HNOTUMLMNAHSD17B10 | |
| Bromide SCHEMBL3533557 | 0.74 | KDM4E (0.51) | CYP19A1LTA4HNOTUMLMNAHSD17B10 | |
| SCHEMBL27968872 | 0.73 | LMNA (0.69) | CYP19A1LTA4HLMNATSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084618-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AADAC, NISCH, PAICS | TLR8 3783/4885CYP19A1 983/4885LTA4H 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.